{"id":4423,"date":"2019-03-26T06:21:21","date_gmt":"2019-03-26T06:21:21","guid":{"rendered":"https:\/\/www.erdheim-chester.org\/?post_type=study_trials&#038;p=4423"},"modified":"2019-03-26T06:21:21","modified_gmt":"2019-03-26T06:21:21","slug":"observational-multi-center-study-on-erdheim-chester-disease-treated-with-anakinra","status":"publish","type":"study_trials","link":"https:\/\/www.erdheim-chester.org\/nb\/study_trials\/observational-multi-center-study-on-erdheim-chester-disease-treated-with-anakinra\/","title":{"rendered":"Observational  Multi-center Study on Erdheim-Chester Disease treated with Anakinra"},"content":{"rendered":"<p><strong>Form\u00e5let med studien:<\/strong>&nbsp; To establish the objective efficacy and safety results recorded with Kineret\u00ae (Anakinra) for ECD patients and its effect on various symptoms and organs.&nbsp; This study is opened to ECD patients who are or have been previously treated with Kineret\u00ae (Anakinra).<\/p>\n<p><strong>Prosjektleder:<\/strong>&nbsp; Dr. Achille Aouba, Department of Internal Medicine and Clinical Immunology, CHU C\u00f4te de Nacre-Caen, FRANCE<\/p>\n<p><strong>Kontaktopplysninger:<\/strong>&nbsp; achille.aouba@gmail.com or aouba-a@chu-caen.fr; Tel: 00 33 2 31 06 45 79;&nbsp; Fax: 00 33 2 31 06 49 54<\/p>\n<p><strong>\u00d8nsket pasientmedvirkning:<\/strong>&nbsp; Consent to have your doctor supply the principal investigator with information about your case.&nbsp; You will be asked to agree to have the following information shared:<\/p>\n<ul>\n<li>Demographic data in the form of your initials, weight, gender and date of birth<\/li>\n<li>Clinical, laboratory and radiological data before, during and possibly after treatment with Kineret\u00ae to establish whether or not the treatment was effective and well tolerated with reference to every symptom and organ<\/li>\n<li>Therapeutic data concerning the Kineret\u00ae treatment start dates and any treatments administered before or after Kineret\u00ae with details of the results, tolerance and reasons for introducing or discontinuing treatment, as applicable.<\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>Study Objective:&nbsp; To establish the objective efficacy and safety results recorded with Kineret\u00ae (Anakinra) for ECD patients and its effect on various symptoms and organs.&nbsp; This study is opened to [&hellip;]<\/p>\n","protected":false},"featured_media":0,"parent":0,"menu_order":0,"template":"","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","cybocfi_hide_featured_image":"","wds_primary_study_trials_cat":0,"_links_to":"","_links_to_target":""},"study_trials_cat":[33],"class_list":["post-4423","study_trials","type-study_trials","status-publish","hentry","study_trials_cat-observational"],"_links":{"self":[{"href":"https:\/\/www.erdheim-chester.org\/nb\/wp-json\/wp\/v2\/study_trials\/4423","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.erdheim-chester.org\/nb\/wp-json\/wp\/v2\/study_trials"}],"about":[{"href":"https:\/\/www.erdheim-chester.org\/nb\/wp-json\/wp\/v2\/types\/study_trials"}],"wp:attachment":[{"href":"https:\/\/www.erdheim-chester.org\/nb\/wp-json\/wp\/v2\/media?parent=4423"}],"wp:term":[{"taxonomy":"study_trials_cat","embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/nb\/wp-json\/wp\/v2\/study_trials_cat?post=4423"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}